Nycomed and Almirall have entered a co-branding agreement for the commercialization of Roflumilast in Spain. A once-daily tablet for patients with chronic obstructive pulmonary disease (COPD), Roflumilast is orally administered phosphodiesterase 4 (PDE4) enzyme inhibitor, and the first oral anti-inflammatory treatment for COPD.
“This product, an entirely new class of treatment, has a strong strategic fit in our business and is fully complementary with other bronchodilator treatments in COPD such as our R&D product aclidinium bromide which is expected to be filed this year,” said Luciano Conde, Almirall’s chief operating officer.
“Since our local launch earlier this year, we have received a very positive response from Spanish physicians, which confirms our conviction of the potential of this important new approach for the treatment of COPD,” said Guido Oelkers, Nycomed’s executive vice president of commercial operations.
Release Date: May 5, 2011
Source: Almirall and Nycomed
